Severe Gastritis after Administration of Nivolumab and Ipilimumab

Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies. As these inhibitors improve antitumor immunity via T-cell modulation, immune-mediated adverse events associated with T-cell activation, such as c...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Case Rep Oncol
Egile Nagusiak: Nishimura, Yoshito, Yasuda, Miho, Ocho, Kazuki, Iwamuro, Masaya, Yamasaki, Osamu, Tanaka, Takehiro, Otsuka, Fumio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: S. Karger AG 2018
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6120399/
https://ncbi.nlm.nih.gov/pubmed/30186138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000491862
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak